Zoll Respicardia INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersMinnetonka, MN
US patents13
SAM.gov UEIET88RNQLK4R7
CAGE code848R7
Incorporated inDE
- implantable device
- treat moderate
- severe central sleep apnea
- adults
- restores
- breathing
- Transvenous
- Stimulation
Named on the company’s own website, read SEP 9, 2026
Patents
13 US patents granted 2021–2025, 13 of them in the five years to SEP 2025.
Medical technology 13
- Systems for treating disordered breathing by comparing stimulated and unstimulated breathingUS 12,420,092 · granted SEP 23, 2025
- Monitoring system and user interface for monitoring implantable disordered breathing treatment systemsUS 12,414,709 · granted SEP 16, 2025
- Transvascular medical leadUS 12,233,259 · granted FEB 25, 2025
- Medical lead and implantationUS 12,233,258 · granted FEB 25, 2025
- Transvenous phrenic nerve stimulation systemUS 12,179,014 · granted DEC 31, 2024
Newest 5 shown · Granted to Zoll Respicardia, INC. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Zoll Respicardia INC | Minnetonka | MN | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.